Cytonics on SeedInvest

Relief for Osteoarthritis


see other companies in category:

Cytonics Website

minimum raise


maximum raise


start date


stop date


security type

Convertible Note

investment minimum


raised to date


reporting date


number of investors

Not Known

percent of minimum raised


percent of maximum raised


likelihood of reaching max

Likely to Reach Max

dollars per day to reach max


dollars per day committed


dollars per day - category-


dollars per day committed - all companies

More SEC Filing Data on Cytonics from

Cytonics, with a valuation cap of $32.4 million, is raising Series C funding on SeedInvest. The company is a leader in regenerative medicine and has developed innovative therapies for musculoskeletal diseases like osteoarthritis. Cytonics has created an Autologous Platelet Integrated Concentration system that concentrates A2M from patients’ blood to treat their own damaged joints. Cytonics was founded by Gaetano Scuderi, a leading orthopedic surgeon with over 21 years of experience. The company has already raised $15 million in previous rounds of funding and the current crowdfunding round has a round size of $1 million. Cytonics has received $1.8 million in government grants from the NIH and has 6 issued and 9 pending patents.